Adverse Drug Reactions of Bleomycin
Beyond pulmonary toxicity, bleomycin causes significant dermatologic reactions (occurring in 50% of patients), acute hyperpyrexic/idiosyncratic reactions (1% in lymphoma patients), vascular toxicities, and various systemic effects that require vigilant monitoring. 1
Major Non-Pulmonary Adverse Reactions
Dermatologic and Mucocutaneous Toxicity (Most Common)
Skin reactions occur in approximately 50% of treated patients and represent the most frequent non-pulmonary adverse effect 1, 2:
- Flagellate erythema - a distinctive "whipped" appearance pattern that is pathognomonic for bleomycin 3
- Hyperpigmentation and dermatographic pigmentation upon scratching
- Erythema, rash, striae, and vesiculation
- Hyperkeratosis and nail changes
- Alopecia, pruritus, and stomatitis
- Scleroderma-like skin changes
- Skin toxicity typically develops in the second and third week of treatment after 150-200 units have been administered and is cumulative dose-related 2
- Discontinuation is required in 2% of patients due to severe skin toxicity 2
Important caveat: Skin changes are thought to be unrelated to lung toxicity, so their presence does not predict pulmonary complications 1.
Acute Hyperpyrexic/Idiosyncratic Reactions (Life-Threatening)
This occurs in approximately 1% of lymphoma patients but <0.5% in solid tumor patients 2, 4:
- Presents with hypotension, mental confusion, high-grade fever, chills, and wheezing
- Clinically mimics anaphylaxis and can progress to cardiovascular collapse and death 5
- Usually occurs after the first or second dose, making early monitoring critical 2
- Can be immediate or delayed for several hours 2
- Mechanism involves release of endogenous pyrogens from host cells and induction of TNF-alpha 6
Management approach: Symptomatic treatment including volume expansion, pressor agents, antihistamines, and corticosteroids 2. Critical monitoring point: Careful observation is essential after the first two doses 2.
Important note: Test dosing does NOT predict when reactions will occur, as onset can happen with any dose at any time - routine test dosing is not recommended 4.
Vascular Toxicities
Vascular complications are clinically heterogeneous and particularly concerning when bleomycin is combined with other antineoplastic agents 2:
- Myocardial infarction
- Cerebrovascular accident (stroke)
- Thrombotic microangiopathy (hemolytic uremic syndrome)
- Cerebral arteritis
- Raynaud's phenomenon - especially when combined with vinblastine with or without cisplatin 2
The exact mechanism remains unclear, but multiple factors may contribute including the disease itself, underlying vascular compromise, bleomycin, other chemotherapy agents, or hypomagnesemia 2.
Systemic and Constitutional Symptoms
- Fever, chills, and vomiting are common 2
- Anorexia and weight loss that may persist long after medication termination 2
- Malaise 2
- Pain at tumor site 2
- Phlebitis and other local injection site reactions 2
Renal and Hepatic Toxicity
Renal or hepatic toxicity can occur at any time after initiation 2:
- Presents initially as deterioration in renal or liver function tests
- Since bleomycin is 70% renally excreted, concomitant cisplatin use increases risk due to cisplatin-induced renal toxicity prolonging bleomycin half-life 1
- Renal function should be checked prior to every cycle 1
Gastrointestinal Toxicity
Severe gastrointestinal toxicities have been reported, though less commonly documented 7.
Pleuropericarditis
Sudden onset of acute chest pain syndrome suggestive of pleuropericarditis has been reported during bleomycin infusions 2. Each patient requires individual evaluation, though further courses are not necessarily contraindicated 2.
Risk Factors Requiring Caution
There are no absolute contraindications to bleomycin, but exercise caution with 1:
- Increasing age (patients >40 years have significantly increased risk)
- Significant smoking history (including former smokers)
- Reduced renal function
- Pre-existing lung disease (particularly fibrosis or symptomatic pathology)
- Multiple risk factors compound the risk
Monitoring Strategy
Before and after every cycle, use a toxicity checklist that includes 1:
- New cough (most sensitive symptom for any toxicity)
- Dyspnea
- Skin changes
- Constitutional symptoms
- Renal function tests
Post-treatment considerations: Patients receiving >300 units should receive a post-treatment CT scan, with further investigations being symptom-led 1.